SEC Comment Letter for Axovant Gene Therapies Ltd. (CIK 0001636050) — Oct 8, 2020

Axovant Gene Therapies Ltd. (CIK 0001636050)
Date: Oct. 8, 2020 · CIK: 0001636050 · Accession: 0000000000-20-009489

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-249279

Date

October 7, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Axovant Gene Therapies Ltd. (CIK 0001636050)

Letter

United States securities and exchange commission logo October 7, 2020 David Nassif, Esq. Principal Financial Officer and General Counsel Axovant Gene Therapies Ltd. Suite 1, 3rd Floor 11-12 St. James’s Square London SW1Y 4LB, United Kingdom Re:Axovant Gene Therapies Ltd. Registration Statement on Form S-4 Filed October 2, 2020 File No. 333-249279 Dear Mr. Nassif: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John T. McKenna, Esq.

Show Raw Text

United States securities and exchange commission logo
October 7, 2020
David Nassif, Esq.
Principal Financial Officer and General Counsel
Axovant Gene Therapies Ltd.
Suite 1, 3rd Floor
11-12 St. James’s Square
London SW1Y 4LB, United Kingdom
Re:Axovant Gene Therapies Ltd.
Registration Statement on Form S-4
Filed October 2, 2020
File No. 333-249279
Dear Mr. Nassif:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John T. McKenna, Esq.

SecProbe.io